ChinaPeptides: difference between revisions
Diff·revision 11 → 12·15:24, 2 Feb 2025
Difference between revision 11 and revision 12 of ChinaPeptides. 3 lines changed; the page grew by 375 bytes.
| Revision 11 — 21:59, 22 Jan 2025 MelanocortinMil (talk) split overlong sentence 6,159 bytes +642 | Revision 12 — 15:24, 2 Feb 2025 GroupBuyGalen (talk) serial comma per PP:MOS 6,534 bytes +375 | ||
|---|---|---|---|
| 1 | {{Infobox organisation | 1 | {{Infobox organisation |
| 2 | | name = ChinaPeptides Co., Ltd. (QYAOBIO) | 2 | | name = ChinaPeptides Co., Ltd. (QYAOBIO) |
| + | 3 | | subtitle = Organisation | |
| 3 | | image = facility.svg | 4 | | image = facility.svg |
| 4 | | caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | 5 | | caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. |
| ⋮ | ⋮ | ||
| 40 | | SARMs | Bulk | Certificate, purity | | 41 | | SARMs | Bulk | Certificate, purity | |
| 41 | | Raw materials and oils | Bulk | Certificate with identity and purity; specification sheet on request | | 42 | | Raw materials and oils | Bulk | Certificate with identity and purity; specification sheet on request | |
| + | 43 | ||
| + | 44 | A custom-synthesis house and a stock distributor differ in the risks a purchaser carries. Custom work introduces the possibility of a synthesis that is technically successful but not the sequence intended; stock distribution introduces the possibility of a mislabelled vial. Neither risk is hypothetical and the mitigations differ.{{r|usp1503}} | |
| 42 | 45 | ||
| 43 | == References == | 46 | == References == |